Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

SGLT2 inhibitor use may help stabilize eGFR levels for patients with autosomal dominant polycystic kidney disease and type 2 diabetes, according to study data.“Given its unique pathophysiology, ...

Despite incomplete evidence, longevity enthusiasts are experimenting with SGLT2 inhibitors in their quest to live healthier ...

Initially used for blood glucose control, the medications reduce cardiovascular events and mitigate heart failure hospitalization, regardless of diabetes status.

For patients with acute MI at increased risk for HF, empagliflozin showed cardiorenal benefits and was safe to initiate early ...

SGLT2 inhibitors are a common treatment for type 2 diabetes. Find out about what medications are available and their benefits and risks.

SGLT2 inhibitors did not reduce the risk for adverse liver outcomes more than DPP-4 inhibitors in patients with type 2 diabetes and metabolic dysfunction–associated steatotic liver disease.

Israel: A new study published in JAMA Network Open highlights a key safety insight for patients with type 2 diabetes taking ...

SGLT2 inhibitors have diuretic and anti-inflammatory effects that may contribute to improved outcomes in patients with PAH, particularly for those who have left-sided heart disease or other ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in ...

SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

Use of SGLT2 inhibitors before emergency surgery was not associated with an increased risk for postoperative diabetic ketoacidosis. The FDA previously issued guidance on withholding SGLT2 ...